论文部分内容阅读
目的:观察治疗急性脑梗死(ACI)的疗效和不良反应。方法:治疗组40例静脉滴注奥扎格雷钠,对照组40例静脉滴注丹参粉针,观察两组治疗前后临床神经功能缺损程度评分及血小板聚集率的变化。结果:治疗组总有效率为93.3%,明显高于对照组的65.3%(P<0.01)。治疗组血小板聚集率、神经功能缺损程度评分亦均优于对照组(均P<0.01),以重型患者症状改善最为明显,且无明显不良反应。结论:奥扎格雷钠可以作为ACI的有效药物,且不良反应小,安全有效。
Objective: To observe the curative effect and adverse reaction of treating acute cerebral infarction (ACI). Methods: 40 patients in the treatment group were given intravenous sodium ozagrel and 40 in the control group by intravenous injection of Danshen powder. The changes of clinical neurological deficit score and platelet aggregation rate were observed before and after treatment. Results: The total effective rate in the treatment group was 93.3%, which was significantly higher than that in the control group (65.3%, P <0.01). The platelet aggregation rate and the degree of neurological deficit in the treatment group were also significantly better than those in the control group (all P <0.01). The symptoms in the severe patients were most obviously improved with no obvious adverse reactions. Conclusion: Ozagrel sodium can be used as an effective drug of ACI, and its adverse reaction is small and safe and effective.